Key findings show mean IgA reductions of around 70% from baseline, sustained at 12 weeks at the 700mg dose.

XL‑protein GmbH today announced the launch of PASylANTA Therapeutics GmbH , a new Germany-based biotechnology company focused ...

Jade Biosciences’ JADE101 Phase 1 IgA biomarker win hints at 12-week dosing, but valuation, funding and Phase 2 2027 risks ...

FOBO isn't a Gen Z problem. It's career-long. Why "learn AI or be replaced" is the wrong fear, and "obsolete for what?" the ...

Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans June 1, 2026 8:00 ...

IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an ...

Phase 1 data support TNX-1500 as a potentially first-in-class, best-in-class, third-generation anti-CD40L monoclonal antibody for the prevention ...

The Trump administration is planning to give surplus plutonium from dismantled nuclear bombs to new nuclear startup companies ...

When I first saw the Woojer vest about seven or eight years ago on Kickstarter, I remember thinking that it sounded fun, but ...

Interim Phase 1 data in rheumatoid arthritis expected in 2027 are anticipated to inform indication prioritization across multiple potential autoimmune indications supported by BAFF-R biology JADE201 ...

Nvidia's Ray Reconstruction model for DLSS 4.5 is coming in August and improves graphics in raytracing games like “Cyberpunk ...

HANGZHOU, China, SHANGHAI and BOSTON, June 1, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and ...